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Abstract
Background: Elevated white blood cell counts (WBC) in acute coronary syndromes (ACS)
increase the risk of recurrent events, but it is not known if this is exacerbated by pro-inflammatory
factors. We sought to identify whether pro-inflammatory genetic variants contributed to
alterations in WBC and C-reactive protein (CRP) in an ACS population.
Methods:  WBC and genotype of interleukin 6 (IL-6 G-174C) and of interleukin-1 receptor
antagonist (IL1RN intronic repeat polymorphism) were investigated in 732 Caucasian patients with
ACS in the OPUS-TIMI-16 trial. Samples for measurement of WBC and inflammatory factors were
taken at baseline, i.e. Within 72 hours of an acute myocardial infarction or an unstable angina event.
Results: An increased white blood cell count (WBC) was associated with an increased C-reactive
protein (r = 0.23, p < 0.001) and there was also a positive correlation between levels of β-
fibrinogen and C-reactive protein (r = 0.42, p < 0.0001). IL1RN and IL6 genotypes had no significant
impact upon WBC. The difference in median WBC between the two homozygote IL6 genotypes
was 0.21/mm3 (95% CI = -0.41, 0.77), and -0.03/mm3 (95% CI = -0.55, 0.86) for IL1RN. Moreover,
the composite endpoint was not significantly affected by an interaction between WBC and the IL1
(p = 0.61) or IL6 (p = 0.48) genotype.
Conclusions:  Cytokine pro-inflammatory genetic variants do not influence the increased
inflammatory profile of ACS patients.
Background
There is compelling evidence that systemic inflammation
plays a role in the development and progression of coro-
nary heart disease (CHD) [1]. White blood cell (WBC)
counts are elevated in patients presenting with acute cor-
onary syndromes. Early studies have shown that patients
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with elevated white blood cell (WBC) counts were at
higher risk of mortality and recurrent AMI [2,3]. More
recent studies have confirmed the association between an
elevated WBC and clinical outcomes in AMI patients and
furthermore suggested that WBC could serve as a simple
and inexpensive tool for risk stratification in acute coro-
nary syndromes [4,5].
The pro-inflammatory cytokines IL-1 and IL-6 have also
been implicated in several mechanisms that contribute to
the development of CHD and increased levels of IL-6 are
associated with higher cardiovascular mortality [6]. Pro-
inflammatory cytokines stimulate the liver to synthesize
acute phase proteins, which in turn are associated with a
higher risk of cardiovascular events [6]. For example, C-
reactive protein (CRP) whose concentration in serum is
increased in response to inflammatory stimuli is also ele-
vated in ACS compared to stable angina or vasospastic
angina [7-9]. Elevated CRP is associated with increased
cardiac morbidity [10-12]. Increased levels of fibrinogen,
another acute phase protein are a strong predictor of a
poor outcome in unstable CAD, and are also reported in
patients with asymptomatic atherosclerosis [13-15]. Sim-
ilarly, plasma vWF levels are strongly associated with
ischaemic heart and cerebrovascular disease [16]. Thus, a
variety of inflammation markers are risk factors for myo-
cardial infarction and other acute coronary syndromes
[17-19]. Inflammatory proteins may not only be markers
of disease but may contribute to its pathogenesis. For
example, there is evidence that CRP and fibrinogen pro-
mote vascular inflammation and thrombosis [18,20].
In spite of the mounting evidence implicating a group of
inflammation-related markers and coronary disease, the
mechanisms are still poorly understood. While inflamma-
tion in the vessel wall may be a consequence of environ-
mental factors (infection, tissue injury), it is also possible
that genetic factors contribute to an abnormal or exagger-
ated inflammatory response. Moreover, interactions
between inflammatory markers and variants of throm-
botic genes may contribute to the coronary thrombosis
that underlies ACS. We sought to determine whether the
elevated white cell count in ACS is influenced by pro-
inflammatory genetic variants.
The IL1 chromosomal cluster of genes contains an
extended haplotype spanning the IL1beta and IL1RN
genes [21]. This haplotype is represented by the IL1RN
intronic repeat *2 allele [22]. Carriers of *2 appears to be
over-represented in some diseases associated with inflam-
mation [21,23-25]. IL1 Receptor Antagonist levels are ele-
vated in acute MI, but it is unclear whether the *2 allele
carriers have an altered risk of cardiovascular disease [26-
28]. The role of the IL1 cluster haplotype in modulating
WBC levels in coronary patients has not been investigated,
and we wished to determine if cardiovascular patients car-
rying *2 had an elevated WBC. The IL6 promoter variant -
174G allele is associated with higher levels of acute phase
IL6, with heterozygotes intermediate between the two
homozygotes [29]. The G allele is associated with both
arthritis and susceptibility to Kaposi sarcoma and has
been associated with atherosclerosis [30-32]. We wished
to evaluate whether there the IL6-174GG genotype was
associated with higher WBC than the -174CC genotype.
The hypothesis we wished to test was whether or not the
elevated WBC seen in patients with an acute event is ele-
vated in carriers of pro-inflammatory genetic variants. In
the absence of careful studies of WBC before and after an
acute event, the pathophysiological causation of elevated
WBC in patients that presented with MI is incompletely
understood. The impact of myocardial damage, and
inflammatory states prior to the MI, are likely to be two
important factors, although extent of ischaemia was not
shown to be strongly associated with WBC in another
study [5]. It is unclear if inflammatory responses associ-
ated with IL1 and IL6 cytokines are key to modulating
either of these processes. From a clinical perspective, iden-
tifying any association between pro-inflammatory vari-
ants and WBC (resulting from either process, and
regardless of cause) could provide a perspective on the
anti-inflammatory mechanisms that may be relevant in
improving patient prognosis. Additionally, we examined
the relationship of the pro-inflammatory variants with
CRP, another marker of inflammation, and with variants
in thrombotic genes previously implicated in coronary
thrombosis.
In order to test this hypothesis, baseline white cell counts
around the time of presentation were investigated from
two clinical trial studies (sample sizes of patients with
white cell counts at follow-up were not sufficient to per-
mit a powerful test of such effects at later time points). The
first study was the multinational OPUS-TIMI 16 study
[33]. Patients had to have either acute myocardial infarc-
tion or unstable angina, with an associated high-risk fea-
ture, and be enrolled within 72 hours from the onset of
their acute coronary syndrome. For comparison purposes,
a group of patients with acute myocardial infarction or
unstable angina from the EXCITE trial (who were
recruited at the time of a percutaneous intervention, and
therefore are mainly outside the time period of an acute
event) and a group of patients presenting with stable
angina (also from the EXCITE study) were similarly exam-
ined [34].BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
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Methods
Study population
OPUS TIMI-16 trial
This was the main population for this study. 924 Cauca-
sian patients were recruited within the genetics sub-study
from the OPUS-TIMI 16 trial of the oral platelet glycopro-
tein IIb/IIIa antagonist Orbofiban [33]. Patients were
recruited from 888 hospitals in 29 countries around the
world. Patients received aspirin and were randomised to
receive: (A) 50 mg of orbofiban daily, (B) 50 mg of
orbofiban twice daily for 30 days followed by 30 mg
orbofiban twice daily, or (C) a placebo. The primary com-
posite endpoint was myocardial infarction, recurrent
ischaemia requiring rehospitilisation, urgent revasculari-
sation, stroke and/or death. Inclusion criteria for OPUS
trial: patients with acute coronary syndromes defined as
ischaemic chest pain at rest within 72 hours of randomi-
sation, associated with positive cardiac markers, electro-
cardiographic changes, or prior cardiovascular disease.
602 of the patients presented with MI and 412 with unsta-
ble angina. WBC count and platelet count data at baseline
were available for 732 patients. C-reactive protein and
fibrinogen levels were measured in 297 OPUS TIMI-16
patients.
EXCITE trial
This second study population was studied in order to
determine if any suggestive findings in the OPUS study
were confirmed in coronary patients recruited with stable
angina or ACS outside the immediate time of the acute
event. 531 patients were recruited for the genetics sub-
study from the EXCITE (Evaluation of oral Xemilofiban In
Controlling Thrombotic Events) trial of the oral platelet
glycoprotein IIb/IIIa antagonist Xemilofiban [34]. This
phase 3 trial was a double-blind, randomised, placebo-
controlled study conducted at 412 centers in North and
South America, New Zealand, Europe, Israel, Australia,
and South Africa. Patients were enrolled who had angio-
graphic evidence of clinically significant coronary artery
disease necessitating PTCR. 342 of the subjects presented
with stable angina (SA) while the remainder presented
with ACS (44 MI, 145 unstable angina).
Genotyping, cell counts and biochemical assays
The plasma component was frozen and shipped on dry ice
to Children's Hospital (Boston), where samples were
stored at -70°C. CRP was measured by ELISA (N Latex
CRP assay, Dade Behring, Newark, DE) close to the time
of the index coronary event, at the time of recruitment.
Agarose gel sizing was used to determine the genotype of
variable number tandem repeat (VNTR) in IL1RN, using
the PCR amplification primers previously described [22].
IL-6 genotyping was performed by restriction enzyme
digestion [35]. Genomic DNA amplifications were carried
out in 50 µl reactions containing 50 ng DNA, 1 mM
dNTPs, 1.5 mM MgCl2, 10X Taq polymerase buffer, 1 unit
Taq  polymerase enzyme, 10 pmoles each of sense (5'
ACCTAAGCTGCACTTTTC 3') and antisense primers (5'
ATTTATTGGGGGTTGAG 3'). Amplification consisted of
an initial denaturation step of 94°C for 5 minutes, fol-
lowed by 30 cycles of denaturing at 94°C for 1 minute,
annealing 55°C for 1 min, and elongating at 72°C for 1
minute. PCR product was verified by 2% TBE agarose gel
electrophoresis, stained with ethidium bromide and visu-
alised under ultra-violet (UV) light. Restriction digests
were set up in 40 µl reactions containing 10–20 µl PCR
product, 10X restriction enzyme buffer, 0.5–7.5 units of
restriction enzyme (Hsp92 II) and BSA. The reactions were
incubated at 37°C overnight. Digests were verified on 2%
TBE agarose gels, stained with ethidium bromide and vis-
ualised under UV light. Other genotypes were determined
according to methods described elsewhere, evaluating the
following genetic variants: GPIIIa PLA2, GPIbα-5C, GPIa
807T, E-selectin 128C, P-selectin 715C, vWF-1051 G,
MMP9-1562T, and β-fibrinogen -455A [35].
Statistical methods
The primary hypothesis was to test whether the white cell
count was elevated in OPUS TIMI-16 study ACS patients
who carried pro-inflammatory genetic variants of the
IL1RN and IL6 genes. This hypothesis was formulated in
part because there was adequate power to detect a modest
genetic effect: assuming usual allele frequencies observed
in Caucasians, there is 80% power to detect a difference of
0.52 cells/mm3 in WBC between carriers and non-carriers
of the IL1RN*2 allele, and there is 80% power to detect a
difference of 0.75 cells/mm3 in WBC between the two IL6
homozygotes. Secondary analyses explored whether there
were any associations between IL1RN and IL6 genotype
and other inflammatory markers. Exploratory analyses
investigated the roles of eight other genetic variants. The
variables were summarized using box-plots that indicate
the median and the 25th and 75th percentiles. The box-
plots also include a 95% CI for the median. Analyses in
the EXCITE stable angina (SA) and EXCITE ACS patient
groups were performed for comparison. For these EXCITE
patients, recruitment was not restricted to around the time
of an acute event, and therefore are more indicative of the
counts of WBC and platelets in coronary patients who are
not having acute events.
The 95% confidence intervals for medians were estimates
using a binomial method that makes no assumptions as
to the underlying distribution of the variable. The 95%
confidence intervals for the difference in median WBC
between genotypes were estimated using 10,000 boot-
strap re-samples. Median values for each of the IL1RN and
IL-6 genotypes were compared using the Kruskal-Wallis
rank sum test. The associations between WBC count,BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
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platelet count, C-reactive protein and fibrinogen were
expressed as Spearman rank correlations. The χ2 test was
used when analyzing categorical data. An exploratory
analysis of the association with eight additional genes
considered carrier status for the allelic variant. Analysis
was performed using the STATA (version 7.0: Statacorp,
2001) and S-Plus (version 6: Insightful Corporation,
2001) packages.
Results
Relationship among inflammation-associated measures
An increased white blood cell count (WBC) was associ-
ated with an increased (baseline) platelet count (r = 0.28,
p < 0.001) and C-reactive protein (r = 0.23, p < 0.001).
There was also a positive correlation between levels of β-
fibrinogen and C-reactive protein (r = 0.42, p < 0.0001).
Weaker associations were found between C-reactive pro-
tein and platelet count (a negative correlation, r = -0.12, p
= 0.05), and between troponin and fibrinogen (r = 0.14, p
= 0.04).
Impact of pro-inflammatory genotype upon white cell 
count
The primary hypothesis that we sought to address was
whether the white cell counts of ACS patients were signif-
icantly influenced by pro-inflammatory genotype. Fig. 1a
indicates that the white cell counts were not influenced by
either the IL1RN or their IL6 genotypes. The difference in
median WBC between the two homozygote IL6 genotypes
was 0.21/mm3 (95% CI = -0.41 to 0.77), representing only
6.3% of the inter-quartile range of WBC. The difference in
median WBC between the two homozygote IL1RN geno-
types was -0.03/mm3 (95% CI = -0.55 to 0.86), represent-
ing only 0.9% of the inter-quartile range. Given the
relative rarity of the *2/*2 genotype, we compared the
IL1RN*1/*1 and *1/*2 genotypes, who differ in median
by -0.23/mm3 (95% CI = -0.64 to 0.24) or just 6.8% of the
interquartile range.
Impact of pro-inflammatory genetic variants on other 
inflammation associated measures
Secondary analyses investigated the impact of the pro-
inflammatory gene variants on other inflammatory mark-
ers and on troponin. Platelet count did not significantly
differ according to IL-6 genotype (Fig. 2a). However, the
IL1RN*2/*2 homozygote was associated with a reduced
platelet count. This was nominally significant (p = 0.002),
and after correction for 4 pro-inflammatory genotypes
and the 4 measures investigated this finding remains of
borderline significance (16 tests, corrected p = 0.03). No
associations were found between the genotypes and CRP,
β-fibrinogen or troponin levels (Figure 3a,3b,3c).
To provide an indication of the role of genetic factors ver-
sus other predictors of WBC, we considered those subjects
with measured levels of CRP. CRP variability accounted
for 6.5% of the variance in WBC. Only 1.2% was
explained by the combined effects of IL1RN and IL6 gen-
otypes (excluding other covariates from the model).
When subjects age, sex, smoking status, BMI, and geo-
graphic location together with their levels of CRP were
considered in a single regression model, the proportion of
variance in WBC accounted for by these variables was 0.20
(adjusted R2). Addition of carrier status for the IL1RN*2
and IL6-17G genotypes led to only a marginal increase
(0.21), which is consistent with the findings above that
the genotypes have very little effect. The combined effect
of carrier status for all ten genes (see below) explained at
most (estimate unadjusted for number of variables) only
4.3% of the variation in WBC.
Impact of interaction between WBC and genotype on 
outcome
In the OPUS TIMI-16 study, few patients had a myocardial
infarction during the follow-up period. Therefore we ana-
lysed the composite endpoint, which in addition to myo-
cardial infarction included recurrent angina requiring re-
hospitalisation, urgent revascularisation, death and
stroke. There were relatively few of the latter two end-
points (see Shields et al 2002 for more details [35]). There
were 118 composite endpoints among the 732 patients
with WBC measurements at baseline. There was no signif-
icant association between elevated WBC and CRP
(defined as the top quartile) and the composite endpoint
(relative risk 1.0, CI 0.66–1.5 for WBC and 1.1, CI 0.7, 1.6
for CRP).
We examined whether interactions between WBC and
genotype influenced the composite outcome. Of the 185
subjects with an elevated WBC count, 82 were carriers of
the IL1RN*2 allele and 154 were carriers of the IL6-174G
allele. The hazard ratio for composite events associated
with elevated WBC count for carriers and non-carriers of
the IL1RN*2 allele was 1.2 (0.7, 2.2) and 0.8 (0.5, 1.5),
respectively (interaction p = 0.61, not significant) Simi-
larly, there was no influence on outcome of interaction
between WBC and the IL6-174G allele: the hazard ratio
associated with elevated WBC was 1.0 (0.6, 1.5) for carri-
ers of the IL6-174G allele and 1.1 (0.4, 3.0) for non-carri-
ers (interaction p = 0.48).
30 subjects were carriers of the IL1RN*2 allele and had
elevated CRP, while only 14 patients had elevated CRP
and did not carry the IL6-G allele. The hazard ratio for
composite events associated with elevated CRP was 1.3
(0.7, 2.2) for IL1-RN*2 carriers and 0.6 (0.3, 1.3) for non-
carriers, which was a non-significant interaction (p =
0.09). Similarly the hazard ratio associated with elevated
CRP was 1.1 (0.7, 1.8) for carriers and 1.0 (0.4, 2.7) for
non-carriers of IL6-174G allele (p = 0.89). Thus, patientsBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
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with a high CRP and particular inflammatory genotypes
do not have an altered risk of composite events.
Other genetic factors
Further exploratory statistical analyses considered eight
additional genes (Table 2): GPIa, GPIIIa (PlA2 variant), β-
fibrinogen, MMP-9, GPIbα, (kozak), E-selectin, P-selec-
tin, and vWF in the OPUS-TIMI-16 population. We
present these results here simply for completeness: these
were mainly initially investigated in relation to their
effects on thrombotic outcome, and we did not a priori
anticipate that any these were likely to be associated with
WBC [35]. WBC was not significantly altered by any of
these variants. Platelet counts were significantly higher in
carriers of the PLA2 allele (medians, 204 for non-carrier
versus 215 for carriers, p = 0.04). This is not significant
after correction for multiple testing. Platelet counts were
significantly lower among carriers of the MMP-9T allele (p
= 0.03) and significantly higher among carriers of the P-
selectin-C allele, but these results were not significant after
adjustment for multiple testing.
Stable angina and acute cases sampled outside timeframe 
of acute event (EXCITE study)
In the EXCITE study, the WBC count was significantly
higher among ACS patients than SA patients (median 7.3
For each of the IL1RN and IL-6 genotypes patients the median (central line) is shown Figure 1
For each of the IL1RN and IL-6 genotypes patients the median (central line) is shown. Flanking this is a dark shaded box, repre-
senting the 95% confidence interval of the median. This gives an indication of the confidence in the estimate of the median. The 
white boxes represent the inter-quartile range (from 25th percentile to the 75th percentile), giving an indication of the variability 
in WBC among patients. (a) WBC (cells/mm3) OPUS TIMI-16 ACS patients (b) WBC (109/L) EXCITE stable angina and (c) 
WBC (109/L) EXCITE ACS patient groups.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
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vs. 6.6, p = 0.02, Table 4). WBC counts were clearly lower
than those seen for the OPUS TIMI-16 patients, whose
measurements were close to the time of acute presenta-
tion. In both groups, an increased WBC count was associ-
ated with an increased (baseline) platelet count (r = 0.21,
p < 0.01 for ACS and r = 0.38, p < 0.0001 for SA). The
platelet count did not differ significantly between the SA
and ACS groups in the EXCITE study. Platelet counts were
lower for the OPUS TIMI-16 patients.
In the EXCITE-ACS patients, there were no significant
effects of genotype on white cell count (Fig. 1b). EXCITE-
SA patients (Fig. 1c) had a marginally lower WBC count
among carriers of the IL1RN*2 allele (medians, 6.3
among carriers versus 6.8 among non-carriers, p = 0.03;
not significant after correction for multiple testing).
EXCITE-ACS and EXCITE-SA groups did not show any sig-
nificant effects of genotype on platelet count, including
the IL1RN*2/*2 which was associated with elevated plate-
let count in the OPUS TIMI-16 study (Fig. 2b,2c).
Among EXCITE-ACS patients WBC counts were lower
among carriers of the MMP-9T allele (p = 0.01) and higher
among carriers of β-fibrinogen -455A (p = 0.007), how-
ever, this was of borderline significance after adjustment
for multiple testing (p = 0.05).
Discussion
Common variants of cytokine genes that are contributory
factors in inflammatory conditions have also been
Platelet count (cells/mm3) versus IL1RN and IL-6 genotypes for the (a) OPUS TIMI-16, (b) Platelet count (109/L) EXCITE stable  angina and (c) Platelet count (109/L) EXCITE ACS patient groups Figure 2
Platelet count (cells/mm3) versus IL1RN and IL-6 genotypes for the (a) OPUS TIMI-16, (b) Platelet count (109/L) EXCITE stable 
angina and (c) Platelet count (109/L) EXCITE ACS patient groups. See Fig. 1 for details.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
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implicated in coronary artery disease [27]. For example,
the variable number tandem repeat (VNTR) polymor-
phism in intron 2 of the gene for interleukin-1 receptor
antagonist (IL-1RN), is elevated in patients with MI
[22,26]. It should be emphasized however that associa-
tions of the IL-1RN-VNTR with disease may be related to
either this protein or the interleukin gene cluster, in par-
ticular the IL1-beta gene, whose promoter variants are in
disequilibrium with the VNTR [21,25].
The VNTR polymorphism of the IL1RN gene has 5 alleles
of between 2 and 6 repeats of an 86 bp sequence. The 4
repeat (IL1RN*1) and the 2 repeat sequence (IL1RN*2)
are the most common while the other alleles occur at a
combined frequency of <5%. One of the first studies
which implicated cytokine gene variants in susceptibility
to heart disease reported an association between the *2
allele of IL1RN and single vessel coronary artery disease,
although this was not confirmed in a larger prospective
study [27,28]. There have also been reports of associations
between the *2 allele of IL1RN and several other inflam-
matory diseases where IL-1 has been implicated have also
previously been found [23,24]. In all of these diseases car-
riage of only one copy of the IL1RN*2 was sufficient to
affect disease course.
A G/C polymorphism at position -174 of the interleukin-
6 promoter that has been associated with raised levels of
IL-6 and juvenile arthritis has also been associated with
atherosclerosis [30,32]. However, we found no evidence
(a) Fibrinogen (mg/dl) (b), CRP (mg/dl) (c), troponin (ng/ml) levels versus IL1RN and IL-6 genotypes for the OPUS TIMI-16  study Figure 3
(a) Fibrinogen (mg/dl) (b), CRP (mg/dl) (c), troponin (ng/ml) levels versus IL1RN and IL-6 genotypes for the OPUS TIMI-16 
study. See Fig. 1 for details.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
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Table 1: OPUS TIMI-16 study: Correlations (r) among White Blood Cell count (WBC), Platelet count, C-reactive protein (CRP), 
Fibrinogen protein and troponin T.
Platelet CRP Fibrinogen Troponin T
WBC 0.28 (<0.0001) 0.23 (0.0003) 0.10 (0.13) 0.29 (0.0001)
Platelet -0.12 (0.05) 0.02 (0.78) -0.04 (0.55)
CRP 0.42 (<0.0001) 0.41 (<0.0001)
Fibrinogen 0.14 (0.04)
1Values are for measurements made at time of recruitment in the OPUS TIMI-16 study. P-values are shown in parentheses.
Table 2: OPUS TIMI-16 study: Distribution of genotypes n (%)
Zero One Two
IL1RN*2 510 (55.2) 354 (38.3) 60 (6.5)
IL6-174G 180 (19.5) 466 (50.5) 276 (29.9)
GPIa 807T 315 (34.1) 449 (48.6) 160 (17.3)
GPIIIa PLA2 680 (73.6) 222 (24.0) 22 (2.4)
Fibrinogen -455A 587 (63.6) 299 (32.4) 37 (4.0)
MMP9-1562T 660 (71.4) 246 (26.6) 18 (2.0)
GP1bα-5T 711 (77.0) 200 (21.7) 12 (1.3)
E-selectin 128C 731 (79.2) 182 (19.7) 10 (1.1)
P-selectin 715C 746 (81.0) 166 (18.0) 9 (1.0)
vWF-1051G 381 (41.3) 416 (45.1) 125 (13.6)
Table 3: EXCITE study: Distribution of genotypes n (%)
Zero One Two
Stable
IL1RN*2 193 (56.6) 125 (36.7) 23 (6.7)
IL6-174G 58 (17.0) 168 (49.1) 116 (33.9)
ACS
IL1RN*2 93 (49.2) 80 (42.3) 16 (8.5)
IL6-174G 35 (18.5) 95 (50.3) 59 (31.2)
Table 4: OPUS TIMI-16 study: WBC Median (Q1, Q3)
Gene Zero One Two
OPUS
IL1RN*2 8.2 (6.6, 10.0) 7.9 (6.6, 10.0) 8.1 (7.4, 10.2)
IL6-174G 8.1 (6.7, 9.6) 8.1 (6.6, 10.0) 8.3 (6.7, 10.3)
EXCITE Stable
IL1RN*2 6.8 (5.8, 8.3) 6.4 (5.4, 7.6) 6.2 (5.6, 7.3)
IL6-174G 6.6 (5.3, 7.5) 6.7 (5.7, 8.2) 6.5 (5.4, 8.1)
All genotypes 6.6 (5.6–7.9)
EXCITE ACS
IL1RN*2 7.1 (5.8, 8.6) 7.5 (5.7, 8.6) 6.3 (5.7, 7.3)
IL6-174G 7.5 (5.8, 8.8) 7.3 (5.8, 8.7) 6.8 (5.7, 8.3)
All genotypes 7.3 (5.8, 8.6)BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
Page 9 of 11
(page number not for citation purposes)
that this variant influenced WBC or CRP in the OPUS
TIMI-16 patients with ACS. A similar lack of association
was observed in a smaller study of 111 patients with cor-
onary artery disease [29].
As the relationship between inflammatory markers and
ACS disease state and thrombotic disease outcome is
likely to be complex, we explored for multiple gene/mark-
ers interactions. We found no association between WBC
and pro-inflammatory cytokine genotypes of the IL1RN
and IL6 genes. Since these variants appear to contribute to
pro-inflammatory non-cardiovascular diseases, and possi-
bly also to atherosclerotic disease, this finding is of some
interest. Since the genotypes did not determine the levels
of the acute phase reactants CRP, it is plausible that the
pro-inflammatory state seen in ACS patients is not
dependent on the IL1-IL6 cytokine pathways. It may
instead be a reaction to systemic atherosclerosis and
inflammation in regions of myocardial ischaemia,
although the extent of ischaemia has not been found to
strongly predict the degree of WBC elevation [5]. Poly-
morphism in the CRP gene influencing CRP level does not
appear to impact upon CHD [36]. Again, this suggests that
WBC and CRP may reflect, rather than cause, the disease
states. Future large studies with measurements of WBC
and troponin before and after acute events may provide a
better indication of whether genetic factors may interact
with myocardial necrosis.
Negative findings such as this one are only valuable when
the sample size has sufficient power to estimate the confi-
dence that a certain risk is unlikely to be conferred. For the
IL-6 variant, the difference in median WBC count between
the two homozygotic IL6 genotypes is estimated to range
between -0.41 and +0.71 (95% confidence interval). This
range only represents approximately 1% of the interquar-
tile range of the WBC variable. Thus, we are confident in
concluding that the genotype is very unlikely to have a
clinically relevant impact on the variation in WBC, and
this study has good power to make this conclusion. We
are equally confident in our conclusion that IL1RN geno-
type has little effect on WBC in the OPUS TIMI-16 study
population around the time of acute presentation.
Inflammatory and thrombotic mechanisms have com-
mon components and are closely related. Therefore, we
examined for the effects on markers of inflammation of
both inflammatory and thrombotic genes. While a previ-
ous smaller study found an association between platelet
count and IL6 genotype in healthy subjects, we failed to
observe any such association in the large ACS population
of the OPUS TIMI-16 study [37]. Instead we found sugges-
tive evidence that IL1RN 2/2 genotype is associated with a
Table 5: OPUS TIMI-16 study: Platelet count median (Q1, Q3).
Gene Zero One Two
OPUS
IL1RN*2 209 (179, 247) 208 (180, 242) 185 (163, 219)
IL6-174G 205 (180, 239) 212 (180, 245) 204 (176, 242)
EXCITE Stable
IL1RN*2 233 (191, 258) 219 (187, 247) 229 (183, 273)
IL6-174G 214 (191, 256) 225 (186, 258) 220 (191, 251)
EXCITE ACS
IL1RN*2 299 (195, 259) 217 (186, 249) 217 (195, 256)
IL6-174G 225 (196, 251) 218 (181, 257) 221 (197, 255)
Table 6: OPUS IMI16 study: Median (Q1, Q3) values for fibrinogen, CRP, and Troponin T.
Gene Zero One Two
IL1RN*2
Fibrinogen 300 (233, 390) 288 (226, 363) 251 (154, 331)
CRP 1.5 (0.6, 4.9) 1.0 (0.4, 3.6) 0.5 (0.3, 3.4)
Troponin 4.5 (0.5, 14.2) 3.9 (0.2, 12.9) 4.8 (0.4, 8.4)
IL6-174G
Fibrinogen 287 (225, 374) 287 (226, 376) 304 (237, 383)
CRP 1.1 (0.5, 3.6) 1.2 (0.6, 4.0) 1.2 (0.5, 5.0)
Troponin 4.6 (0.1, 12.5) 2.5 (0.2, 13.8) 5.7 (0.6, 14.4)BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/13
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lower platelet count. Further analyses are required in a
separate and larger population to confirm this result.
Interleukin-1β is the product of one of the genes in the
IL1RN-VNTR associated gene cluster, and it may play a
role in platelet function, since it is translationally up-reg-
ulated in activated platelets [21,38].
Finally, it must be pointed out that the findings of this
study within the OPUS TIMI-16 trial relate only to
patients recently diagnosed with a recent acute coronary
event. This may not relate to the potential relationship
among pro-inflammatory variants and WBC in other con-
texts, such as normal cohorts or cohorts exposed to
infection.
Conclusions
We conclude that cytokine pro-inflammatory genetic var-
iants, which have an impact on inflammatory disease
processes do not markedly influence the inflammatory
profile of patients presenting with ACS. The cytokine
pathways may therefore not be pivotal determinants of
the increased level of inflammatory activity in these
patients.
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